Research ArticleArticles on Covid-19

Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2

STEVEN LEHRER and PETER H. RHEINSTEIN
In Vivo September 2020, 34 (5) 3023-3026; DOI: https://doi.org/10.21873/invivo.12134

Article Information

vol. 34 no. 5 3023-3026
DOI 
https://doi.org/10.21873/invivo.12134
PMID 
32871846
Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received June 1, 2020
  • Revision received June 18, 2020
  • Accepted June 19, 2020
  • Published online August 31, 2020.
Copyright & License 
Copyright © 2020 The Author(s). Published by the International Institute of Anticancer Research.

Author Information

  1. STEVEN LEHRER1,*⇑ and
  2. PETER H. RHEINSTEIN2,*
  1. 1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, U.S.A.
  2. 2Severn Health Solutions, Severna Park, MD, U.S.A.
  1. Correspondence to: Dr. Steven Lehrer, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, 1 Gustave L. Levy Place, Box 1236, New York City, 10029 NY, USA. E-mail: steven.lehrer{at}mssm.edu

  1. ↵* These Authors contributed equally to this study.

View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
STEVEN LEHRER, PETER H. RHEINSTEIN
In Vivo Sep 2020, 34 (5) 3023-3026; DOI: 10.21873/invivo.12134
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords